1144523-66-9

Upstream product

• 437-29-6 tris(4-fluorophenyl)bismuthane 
• 1011-65-0 5-methoxycarbonylindole 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 352-34-1 4-fluoro-1-iodobenzene 

Downstream Products

• 243467-60-9 (1-(4-fluorophenyl)-1H-indole-5-carboxylic acid) 
• 1373356-16-1 1-(4-fluorophenyl)-5-({3-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]azetidin-1-yl}carbonyl)-1H-indole 
• 1429022-30-9 1-(4-fluorophenyl)-5-({3-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]azetidin-1-yl}carbonyl)-1H-indole hydrochloride 
• 1252765-13-1 JNJ-42226314 
• 1429022-29-6 (1-(4-fluorophenyl)-1H-indol-5-yl)(3-(piperazin-1-yl)azetidin-1-yl)methanone 
• 1252765-77-7 2,2,2-trifluoro-1-(4-(1-(1-(4-fluorophenyl)-1H-indole-5-carbonyl)azetidin-3-yl)piperazin-1-yl)ethanone 
• 1252777-85-7 C₂₆H₂₆FN₅O₂S 

Relevant academic research and scientific papers

PIPERAZINE DERIVATIVES AS MAGL INHIBITORS

The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Copper-catalyzed N-arylation of azoles and diazoles using highly functionalized trivalent organobismuth reagents

The N-arylation of indoles, indazoles, pyrroles, and pyrazoles using highly functionalized trivalent arylbismuth reagents is reported. The reaction is promoted by a substoichiometric amount of copper acetate, and it tolerates a wide diversity of functional groups on the azole and the organobismuth reagent. The method is also applied to the N-arylation of tryptophan derivatives. This journal is the Partner Organisations 2014.

PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: wherein Y, Z, and R are defined herein.

MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS

Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.

CRYSTALLINE HYDROCHLORIDE SALT OF (1- (4 -FLUOROPHENYL) - 1H - INDOL - 5 - YL) - (3- (4- (THIAZOLE - 2 - CARBONYL) PIPERAZIN- 1 - YL) AZ ETIDIN- 1 -YL) METHANONE AND ITS USE IN THE TREATMENT OF PAIN AND METABOLIC DISORDERS

The present invention relates to a crystalline hydrochloride salt of (l-(4-fluorophenyl)-lH-indol-5-yl)(3-(4-(thiazole-2-carbonyl)piper- azin-l-yl)azetidin-l-yl)methanone, Formula (I) methods of making said salt, pharmaceutical compositions contain? ing said salt, and the use of said salt in the treatment of pain and dis? eases that cause such pain, and metabolic disorders such as, obesity, hyperphagia, and diabetes.

DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (Ia) and Formula (Ib) as follows: wherein Y, Z, and n are defined herein; and wherein Yb and Zb are as defined herein.

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I), wherein Y, Z, R1, and s are defined herein.

INDOLE DERIVATIVES USEFUL AS PPAR ACTIVATORS

There is provided according to the invention novel compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: (I) useful as PPAR activators.